Abstract

ObjectiveTo assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future
C Palmieri ... T Robinson
Clinical Oncology | VOL. 32
C Palmieri, et. al.C Palmieri ... T Robinson
14 May 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Graham Ross ... Mark C Benyunes
Lancet Oncology | VOL. 14
Graham Ross, et. al.Graham Ross ... Mark C Benyunes
18 Apr 2013
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy?
Maura N Dickler ... Gary A Ulaner
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | VOL. 33
Maura N Dickler, et. al.Maura N Dickler ... Gary A Ulaner
20 Jul 2015
Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study
S Verma ... C Lee
Cancer Research | VOL. 79
S Verma, et. al.S Verma ... C Lee
15 Feb 2019
View more papers

More From: BMJ

Paper Title
Journal
Date
Author
New WHO guidance can support transparent and informed engagement with the private sector
Kent Buse ... Monika Arora
BMJ | VOL. 385
Kent Buse, et. al.Kent Buse ... Monika Arora
29 May 2024
Labour’s pledge to clear NHS waiting list within five years will be tough to achieve, say leaders
Matthew Limb
BMJ | VOL. 385
Matthew LimbMatthew Limb
29 May 2024
Sudan: Aid workers describe “bloodbath” in Darfur as hospitals are repeatedly attacked
Elisabeth Mahase
BMJ | VOL. 385
Elisabeth MahaseElisabeth Mahase
29 May 2024
US state classifies mifepristone and misoprostol as dangerous controlled substances
Janice Hopkins Tanne
BMJ | VOL. 385
Janice Hopkins TanneJanice Hopkins Tanne
29 May 2024
View more papers